Pretransplant cmv-specific t-cell immunity but not dose of antithymocyte globulin is associated with recovery of specific immunity after kidney transplantation

Background: This is a prospective, multicenter, observational study in cytomegalovirus (CMV)-seropositive kidney transplant recipients with pretransplant CMV-specific cell-mediated immunity (CMV-CMI) receiving antithymocyte globulin (ATG). We aimed to investigate posttransplant CMV-CMI over time and...

Descripción completa

Detalles Bibliográficos
Autores: Páez-Vega, A. (Aurora)|||/items/85267b8d-ba58-43cd-a41a-fd4e1e084586, Cantisán, S. (Sara)|||/items/5893bbb3-9f83-4549-b080-ff30e2c31dc3, Agüera, M.L. (Maria L.)|||/items/4ef663e9-623d-4e97-9592-5b1e21a5b795, Suñer, M. (Marta)|||/items/08268ea5-4898-452a-9199-cd015fe7bab3, Facundo, C. (Carmen)|||/items/70ca3815-eaa9-4247-9583-3797492d89ae, Yuste-Ara, J.R. (José Ramón)|||/items/b1d86a95-66bf-4b71-aae3-7f93b5d39a17, Fernández-Ruiz, M. (Mario)|||/items/ca572da8-1a65-4058-adac-023393ecf09c, Montejo, M. (Miguel)|||/items/b57073a5-7e79-4009-8164-5e413784ae7f, Redondo-Pachón, D. (Dolores)|||/items/ba3375f5-db45-469f-abb3-9c991b2f2ca4, López-Oliva, M.O. (María O.)|||/items/a91c8e29-d7cd-4091-a078-b20c18ca9907, Fernández-Rodríguez, A. (Ana)|||/items/6e496e15-b480-4ac0-ab1c-f71a552e9f93, Fariñas, M.C. (Maria C.)|||/items/8974474e-bbb6-4536-8718-05dc383cd9e6, Hernández, D. (Domingo)|||/items/e7457bc1-ddc5-4f87-84f5-9418dd14c4b0, Len, O. (Oscar)|||/items/a8d24e26-d99f-4d42-92c8-d74f40ad3135, Munoz-Garrido, P. (Patricia)|||/items/5791e618-3b5a-4fee-935b-e4ef9a792005, Valle-Arroyo, J. (Jorge)|||/items/83bd7028-f60b-469b-9e33-86194e78fa39, Rodelo-Haad, C. (Cristian)|||/items/2577fc6c-123e-40c1-a50b-44313f483593, Cordero-Matía, E. (Elisa)|||/items/e68aea31-79bb-4be4-babb-ef287a46e238, Torre-Cisneros, J. (Julián)|||/items/24d004af-398c-4cff-8c0f-a2914b5da4e4
Tipo de recurso: artículo
Fecha de publicación:2021
País:España
Institución:Universidad de Navarra
Repositorio:Dadun. Depósito Académico Digital de la Universidad de Navarra
Idioma:inglés
OAI Identifier:oai:dadun.unav.edu:10171/113877
Acceso en línea:https://hdl.handle.net/10171/113877
Access Level:acceso abierto
Palabra clave:Place-names
Etymology
Tacitus
River Trent Cytomegalovirus infection
Kidney transplant
Kinetics of CMV-specific cell-mediated immunity
QuantiFERONCMV assay
Antithymocyte globulin
Descripción
Sumario:Background: This is a prospective, multicenter, observational study in cytomegalovirus (CMV)-seropositive kidney transplant recipients with pretransplant CMV-specific cell-mediated immunity (CMV-CMI) receiving antithymocyte globulin (ATG). We aimed to investigate posttransplant CMV-CMI over time and the impact of the dose-dependent ATG. Methods: CMV-CMI was assessed at days +30, +45, +60, and +90 after transplantation with the QuantiFERON-CMV assay. A reactive result (interferon-γ [IFN-γ] ≥ 0.2 IU/mL) indicated a positive CMV-CMI. Results: A total of 78 positive CMV-CMI patients were enrolled in the study, of which 59.5% had a positive CMV-CMI at day +30 and 82.7% at day +90. Multivariate logistic regression analysis showed that ATG dose was not associated with positive CMV-CMI at any point. However, pretransplant IFN-γ level (>12 IU/mL vs ≤12 IU/mL) was associated with positive CMV-CMI at day +30 (odds ratio, 12.9; 95% confidence interval, 3.1-53.3; P < .001). In addition, all the patients who did not recover CMV-CMI at day +90 had a pretransplant IFN-γ level ≤12 IU/mL. Conclusions: More than half of CMV-seropositive kidney transplant recipients receiving ATG recover (or maintain) CMV-CMI by the first month after transplantation. The pretransplant IFN-γ level, but not the ATG dose, shows a strong association with the kinetics of this recovery.

Similares en LA Referencia